1 / 28

Designing Medicinal Drugs for Prostate Cancer

Designing Medicinal Drugs for Prostate Cancer. Student: Karen Huang Mentor: Nichole Coleman. Index. Introduction Experiment Results Conclusion. Introduction. 2004 Summer San Francisco State University Dr. Clifford Berkman’s lab

yaakov
Download Presentation

Designing Medicinal Drugs for Prostate Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Designing Medicinal Drugs for Prostate Cancer Student: Karen Huang Mentor: Nichole Coleman

  2. Index • Introduction • Experiment • Results • Conclusion

  3. Introduction • 2004 Summer • San Francisco State University • Dr. Clifford Berkman’s lab • Research Purpose: To make the medicinal drug for prostate cancer.

  4. Introduction • Prostate cancer is one of the most frequently diagnosed cancers among men and the second most common cause of cancer-related deaths in American (second to lung cancer). • About 200,000 men are diagnosed each year. • Reference: Prostate.com

  5. Introduction: Prostate Cancer • Benign or Malignant • Malignant cancer Cells Spread from the prostate to nearby lymph nodes, bones or other organs.

  6. Introduction: PSMA • When A man has prostate cancer, an enzyme called PSMA is located on the surface of the cancer cell • PSMA: Prostate Specific Membrane Antigen • Enzyme is a Protein used to catalyze biological reactions The Enzyme PSMA

  7. What’s going on at the Surface A model for the organization of the PSMA. • E: Catalytic activity • Domain E is responsible for the catalytic activity of the enzyme. • The other Domains has no enzyme activity Prostate Cancer Cell

  8. Introduction: Inhibitors • The Medicinal Drugs we were trying to make this summer are called inhibitors • Inhibitors are compounds that stop the growth of cancer cells • Preliminary Studies done by Dr. Berkman suggest that compounds that look like the one in figure 1, can decrease cancer growth Figure 1

  9. Introduction • X = 4-Cl, 4-OMe, 4-Me, 3,4-Cl2, 4-OPh 3-Cl, 4-tBu, 4-CF3, 4-Br, 3-CF3-4-Cl, 3-Me, 4-N(Me)2, 3-N(Me)2, 3-CF3, 2,4-Cl2, 4-NO2, 3-CF3-4-NO2, 4-NH2, 4-OH, 3-Ome, 4-OiPr, 2-Cl, 2-Me, 2-OMe, 4-F, 3,5-Cl2, 3-NO2, 4-OCH2Ph, The following molecule looks like the drug we are trying to design for prostate cancer. Figure 1 X could be those following molecules.

  10. Introduction • In order to make the compound in Figure 1, the first step is to make the compound in Figure 2. Figure 1 Figure 2

  11. Wanted and Unwanted Compound Wanted Compound Unwanted Compound During the course of the summer, my responsibility was to make the desired molecule above. But we had a lot of problems with the chemistry. Our Desired compound kept isomerizing into the unwanted compound above.

  12. The Experimental The next couple of slides details how the Wanted and Unwanted compounds were made

  13. Experimental: Experiment 1 Reaction Scheme

  14. Experiment Step 1 • Add Dibenzylphosphite to a round bottom flask with a magnetic stir bar. Set this flask on an Ice Bath • Add Potassium hexamethyl disilazane ( KHMDS) drop wise and stir for 1hour Step 2 • Remove the Ice Bath • Add allyl bromide drop wise and stir overnight • At this point the heat conditions will be employed Experiment 1

  15. Experiment Experiment 2…Resaction Scheme Phosphonate Salt Side Product Potassium tert-Butoxide Dibenzylphosphite Allylbromide

  16. Experiment Experiment 2 Step 1 • Add Dibenzylphosphite to a round bottom flask with a magnetic stir bar. Set this flask at room temperature • Add Potassium tert-Butoxide (powder) and stir for 1 hour Step 2 • Add Allyl Bromide drop wise and stir overnight • At this point the heat conditions will be employed

  17. Experiment Work up Procedure (For Both Experiments) • Using a Separatory Funnel, the reaction mixture inside • Add Ethyl Acetate (EtOAc) • Add water • There were two layers present. • organic was at the top • aqueous was at the bottom • Shake the separotory funnel and release aqueous layer • Wash with 10% HCl and shake and release aqueous layer • Wash with NaHCO3 and shake and release aqueous layer • Wash with Sat. NaCl and shake and release aqueous layer • Dry the reaction with Na2SO4 • Filter Na2SO4 and evaporate the solvent

  18. Experiment Test Procedure Once the solvent is evaporated, Run a TLC using • 10% Isopropanol in Hexane • 3% Methanol in Dicholoromethane • Run a Crude NMR • Purification with 3% Methanol in Dichloromethane • Run a Pure NMR • Get the graphs of NMR tests.

  19. Results Comparison The Wanted Compound Allylphosphonate The Unwanted Vinylphosphonate Experiment 1 gave both wanted and unwanted product. Experiment 2 gave only the desired product.

  20. Results Experiment 1 The results of the experiment 1 gave the unwanted compound and a small amount of the wanted compound.

  21. Results Experiment 2 The results of the experiment 2 gave the majority of the wanted compound and a small amount of the starting material. No unwanted product was present.

  22. Results • The reason why I tried experiment 1 under three different conditions is at each temperature condition the major product was the unwanted compound. • By changing the condition we thought that we could produce the wanted compound. We tried experiment 2 only one time and received the wanted compound with the first attempt.

  23. NMR Results The next couple of slides Characterize the Compound found in Experiment 2

  24. Proton NMR test result of an experiment after experiment 2 Benzene Ring Region • This a crude NMR • The Crude NMR is shown to show that the reaction did not produce any of the unwanted compound • There is some allylbromide present. And some EtOAc present but we know that the wanted compound is present because of the Ha and Hb Peaks. Hb Ha Ethyl Acetate

  25. Phosphorus NMR test result of an experiment after experiment 2 Results 25.09 ppm indicates our wanted compound. This test looks like we get the wanted compound.

  26. Conclusion • The wanted compound may not be stable when using the conditions from Experiment 1, because we saw it isomerizing to the unwanted compound. • The wanted compound was formed when we tried Experiment 2. This experiment will be done to conform the results. • Other chemical methods will be used for making the allylphosphonate.

  27. Special Thanks • Dr. Berkman Thanks for helping and teaching • Mentor: Nichole Coleman Thanks for helping and teaching me patiently. • Ms. Elaine Yamaguchi & Mr. Glann Fuller & Wally Yokoyama • American Chemical Society • Mr. Matsumoto • Project Seed Mentors Thanks for helping me. • Project Seed Students Thanks for having lunch with me.^-^

  28. A n d . . . Thank you!

More Related